Results 81 to 90 of about 26,394 (258)
B‐cell lymphomas are hematologic malignancies characterized by poor prognoses. Immunotherapy has revolutionized B‐cell lymphoma treatment by harnessing immune effector cells, but current therapeutic strategies face limitations: suboptimal ...
Yefeng Shen +12 more
doaj +1 more source
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source
This graphical abstract illustrates the prognostic significance of systemic inflammatory markers in Multiple Myeloma (MM). The left panel depicts the immunosuppressive tumor microenvironment, where abundant neutrophils and M2 macrophages promote MM cell survival while lymphocytes are depleted.
Lihong Zhang, Bing Ma, Jingyu Zhang
wiley +1 more source
ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu +5 more
wiley +1 more source
Bispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong +5 more
doaj +1 more source
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu +2 more
wiley +1 more source
Bispecific antibodies in follicular lymphoma
Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
doaj +1 more source
Fatigue in Myasthenia Gravis: Recent Advances and Emerging Concepts
ABSTRACT Fatigue is a common, often disabling symptom in myasthenia gravis (MG), distinct from muscle fatigability, and strongly associated with reduced quality of life. This narrative review examines current evidence on fatigue in MG, its patient impact, and future research directions. Earlier studies, mostly small and heterogeneous, reported a highly
Yvonne J. M. Campman +3 more
wiley +1 more source
The use of immunosuppressive drugs for vitiligo treatment carries a potential risk of increased infection, whereas IFNγ bispecific antibodies represent an alternative therapeutic strategy.
Yuhua Xie +4 more
doaj +1 more source

